CUROCELL INC
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Curocell Completes Korea's First Phase 2 Clinical Trial for Next-Generation CAR-T 2023-11-01 16:23
Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023 2023-06-20 08:01
Curocell announced impressive CR rate in Phase 1 study with anbal-cel, the next generation CD19 CAR-T integrated OVIS™ platform 2022-06-13 19:00
Curocell, Breaks Ground on 'CAR-T Manufacturing GMP Facility' 2021-12-23 20:00
Curocell announces Korean FDA clearance of the IND for CRC01, a first in kind immune checkpoint receptors downregulated CD19 CAR-T therapy 2021-02-22 22:00
1